IBCD 2020 will explore routes through the continually evolving scientific, methodological and regulatory environment for drug and biomarker development. The EORTC, NCI, EMA, and AACR will will work alongside FDA and PMDA specialists to build upon recommendations and action points established upon at the IBCD 2018 edition.
IBCD 2020 will explore routes through the continually evolving scientific, methodological and regulatory environment for drug and biomarker development. The EORTC, NCI, EMA, and AACR will will work alongside FDA and PMDA specialists to build upon recommendations and action points established upon at the IBCD 2018 edition.
Find out more at https://event.eortc.org/ibcd2020/